Inhibrx Biosciences INBX
NASDAQ INBX
$98.19 +2.89 (+3.03%)
At close: Oct 21, 2026 · 4:00 PM EDT

Inhibrx Biosciences (INBX) EBITDA Margin (2023 - 2025)

Updated

Inhibrx Biosciences (INBX) reported EBITDA Margin of -10195.54% for FY2025, up 154385.96 percentage points from -164581.50% in FY2024.

Analysis

Inhibrx Biosciences (INBX) EBITDA Margin (2023 - 2025) Analysis & Trends

  • According to Business Quant data, EBITDA Margin came in at -164581.50% in FY2024 (-152468.72 pp) and -12112.78% in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 35.95%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 49.01%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 6.02%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.11%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 46.01%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -124.26%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 39.16%
10 Inhibrx Biosciences 1.54 Bn 937.90 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -2,007.77%
Dec 31, 2024 -49,239.00%
Jun 30, 2024 -159,600.00%
Dec 31, 2023 -5,308.69%
Sep 30, 2023 -37,213.45%
Jun 30, 2023 -136,813.33%
API Access

Inhibrx Biosciences EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=INBX&period=max&api_key=YOUR_API_KEY